Jardiance | ASweetLife

FDA Approves Glyxambi, New Type 2 Diabetes Medication

The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company’s Glyxambi for treatment of adults with type 2 diabetes. Glyxambi is the first and only diabetes treatment in the U.S. to combine the dual mechanisms of ....

FDA Issues Complete Response Letter for Type 2 Diabetes Drug Empagliflozin

The FDA has issued a complete response letter to Boehringer Ingelheim and Eli Lilly for the New Drug Application (NDA) of the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. The complete response letter referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured.

New Data Shows Empagliflozin Improves Blood Glucose Levels in Type 2 Diabetes Patients

Eli Lilly and Boehringer Ingelheim presented new data from a phase 2b open-label extension study, showing empagliflozin (BI 10773), alone or as an add-on to metformin, reduced hemoglobin A1c (HbA1c or A1c) levels, fasting plasma glucose (FPG) levels and body weight when given to adults with type 2 diabetes for up to 90 weeks...